Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Free Report) – Stock analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of Nanobiotix in a research report issued to clients and investors on Friday, September 25th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.33) per share for the year, down from their previous forecast of $0.37. The consensus estimate for Nanobiotix’s current full-year earnings is ($0.51) per share.
A number of other analysts have also weighed in on NBTX. Guggenheim started coverage on Nanobiotix in a research note on Tuesday, September 15th. They set a “buy” rating and a $64.00 price objective for the company. Leerink Partners lifted their target price on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research note on Thursday, June 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Nanobiotix currently has a consensus rating of “Moderate Buy” and an average price target of $46.67.
Nanobiotix Stock Performance
NBTX opened at $31.50 on Tuesday. The stock’s 50 day simple moving average is $38.51 and its 200 day simple moving average is $37.29. Nanobiotix has a 1 year low of $14.78 and a 1 year high of $57.14.
About Nanobiotix
Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.
Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.
Recommended Stories
- Five stocks we like better than Nanobiotix
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
